www.fdanews.com/articles/122143-biota-acquires-assets-from-prolysis-and-maxthera-for-roughly-11-5m

Biota Acquires Assets from Prolysis and MaxThera for Roughly $11.5M

November 12, 2009

Australian anti-infectives company Biota reported separate agreements to purchase key assets and drug development programs from Prolysis and MaxThera for a total consideration of $11.53 million in cash and shares.
Genetic Engineering & Biotechnology News